Drug Description in Trials / DrugBank / KEGG DRUG
Search results
Showing 1 to 10 of 92 descriptions
| No. | Drug (Description in trials) | DrugBank | KEGG DRUG | KEGG GENES | KEGG PATHWAY | Disease ID | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 11C-ACETATE | [2] Acetate Acetate,Acetic acid C-11 | - | - | - | [4] 6 6, 13, 86, 88 💬
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2 | [18F]Fluoro-2-deoxy-2-D-glucose | [2] D-glucose D-glucose,Dextrose, unspecified form | [1] Glucose
Glucose
💬2. [18F]Fluoro-2-deoxy-2-D-glucose
| - | - | [2] 86 86, 88 💬
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 3 | Acetate | [1] Acetate Acetate | - | - | - | [41] 1 1, 2, 6, 10, 13, 46, 49, 51, 60, 64, 67, 70, 71, 73, 75, 76, 78, 79, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 171, 206, 222, 224, 225, 227, 235, 251, 265, 288, 298, 299 💬 [41] 1, 2, 6, 10, 13, 46, 49, 51, 60, 64, 67, 70, 71, 73, 75, 76, 78, 79, 81, 83, 85, 86, 88, 90, 96 ... 3. Acetate
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 4 | ACT-064992 | - | - | - | - | [5] 51 51, 85, 86, 88, 210 💬
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 5 | ACT-293987 | - | - | - | - | [3] 51 51, 86, 88 💬
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 6 | Adempas | [1] Riociguat Riociguat | [1] Riociguat
Riociguat
💬6. Adempas
| [3] GUCY1A1 GUCY1A1,GUCY1A2, GUCY1B1 💬 | [11] Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 [11] Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signali ... | [5] 51 51, 86, 88, 225, 299 💬
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 7 | Adempas (Riociguat, BAY63-2521) | [1] Riociguat Riociguat | [1] Riociguat
Riociguat
💬7. Adempas (Riociguat, BAY63-2521)
| [3] GUCY1A1 GUCY1A1,GUCY1A2, GUCY1B1 💬 | [11] Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 [11] Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signali ... | [2] 86 86, 88 💬
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 8 | Adempas® | [1] Riociguat Riociguat | [1] Riociguat
Riociguat
💬8. Adempas®
| [3] GUCY1A1 GUCY1A1,GUCY1A2, GUCY1B1 💬 | [11] Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 [11] Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signali ... | [2] 86 86, 88 💬
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 9 | Ambrisentan | [1] Ambrisentan Ambrisentan | [1] Ambrisentan
Ambrisentan
💬9. Ambrisentan
| [1] EDNRA EDNRA 💬9. Ambrisentan
| [7] Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 [7] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin se ... | [7] 51 51, 84, 85, 86, 88, 210, 211 💬
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 10 | Ambrisentan 5 mg | [1] Ambrisentan Ambrisentan | [1] Ambrisentan
Ambrisentan
💬10. Ambrisentan 5 mg
| [1] EDNRA EDNRA 💬10. Ambrisentan 5 mg
| [7] Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 [7] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin se ... | [1] 88 88 💬10. Ambrisentan 5 mg
|